PRESS RELEASE published on 08/01/2025 at 13:00, 4 months 4 days ago Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates Moderna reports Q2 revenue of $0.1B, net loss of $(0.8)B, updates 2025 revenue to $1.5-$2.2B due to shipment timing, improves operating expenses by $400M, reiterates $6B year-end cash balance. FDA approvals for flu vaccine Revenue Moderna Q2 2025 FDA Approvals
BRIEF published on 08/01/2025 at 12:05, 4 months 4 days ago UK Court Confirms Validity of Moderna's EP'949 Patent Patent MRNA Technology Moderna Pfizer/BioNTech UK Court
PRESS RELEASE published on 08/01/2025 at 12:00, 4 months 4 days ago UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech Moderna's EP'949 patent validity upheld by UK Court of Appeal in Pfizer/BioNTech case. Recent legal developments in Europe further strengthen Moderna's intellectual property portfolio MRNA Technology Moderna Pfizer/BioNTech EP'949 Patent UK Court Of Appeal
BRIEF published on 07/30/2025 at 22:10, 4 months 5 days ago Moderna Gains European Approval for New COVID-19 Vaccine COVID-19 Vaccine European Commission Moderna SARS-CoV-2 SPIKEVAX®
PRESS RELEASE published on 07/30/2025 at 22:05, 4 months 5 days ago Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 Moderna receives marketing authorization from the European Commission for updated COVID-19 vaccine Spikevax® targeting SARS-CoV-2 variant LP.8.1 COVID-19 Vaccine European Commission Moderna Spikevax LP.8.1
BRIEF published on 07/28/2025 at 13:05, 4 months 8 days ago Moderna to Present mRNA Therapeutics Data at ESMO Congress 2025 MRNA Therapeutics Moderna Melanoma Bladder Cancer ESMO Congress 2025
PRESS RELEASE published on 07/28/2025 at 13:00, 4 months 8 days ago Moderna Announces Data to be Presented at ESMO Congress 2025 Moderna to present abstracts on investigational mRNA therapeutics at 2025 ESMO Congress. Mini oral presentation on mRNA-4359 and two poster presentations on intismeran autogene Cancer Therapy MRNA Therapeutics Moderna ESMO Congress T-cell Immune Responses
BRIEF published on 07/25/2025 at 14:50, 4 months 10 days ago EMA Recommends Moderna's Updated COVID-19 Vaccine for EU Authorization COVID-19 Vaccine European Commission Moderna EMA Approval SARS-CoV-2 LP.8.1
PRESS RELEASE published on 07/25/2025 at 14:45, 4 months 10 days ago EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1 Moderna's updated COVID-19 mRNA vaccine targeting variant LP.8.1 receives positive CHMP opinion for EU marketing authorization. European Commission to decide for 2025-2026 season COVID-19 Vaccine European Commission Moderna CHMP LP.8.1
BRIEF published on 06/30/2025 at 13:05, 5 months 5 days ago Moderna Reports Positive Phase 3 Results for Seasonal Influenza Vaccine Moderna Influenza Vaccine Phase 3 Results RVE MRNA-1010
Published on 12/05/2025 at 02:35, 10 hours 59 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 12 hours 34 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 29 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 34 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 13:00, 34 minutes ago Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 34 minutes ago Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 29 minutes ago Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 34 minutes ago CGTN:Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 34 minutes ago Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million
Published on 12/05/2025 at 08:45, 4 hours 49 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 34 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 19 hours 49 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 19 hours 50 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health